Nicodème Kalenda Tshilombo
University of Liège
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nicodème Kalenda Tshilombo.
Journal of Pharmaceutical and Biomedical Analysis | 2017
Védaste Habyalimana; Jérémie Kindenge Mbinze; Achille Loconon Yemoa; Christelle Waffo; Tidiane Diallo; Nicodème Kalenda Tshilombo; Justin-Léonard Kadima Ntokamunda; Pierre Lebrun; Philippe Hubert; Roland D. Marini
HIGHLIGHTSSelection of antiretroviral medicines currently used in Rwanda.Application of design of optimization and design space.Optimization of three methods, generic and dedicated.Application of the developed analytical method. ABSTRACT As one of the worlds most significant public health challenges in low‐ and middle‐income countries, HIV/AIDS deserves to be treated with appropriate medicines, however which are not spared from counterfeiting. For that, we developed screening and specific HPLC methods that can analyze 18 antiretroviral medicines (ARV) and 4 major excipients. Design of experiments and design space methodology were initially applied for 15 ARV and the 4 excipients with prediction thanks to Monte Carlo simulations and focusing on rapidity and affordability thus using short column and low cost organic solvent (methanol) in gradient mode with 10 mM buffer solutions of ammonium hydrogen carbonate. Two other specific methods dedicated to ARV in liquid and in solid dosage formulations were also predicted and optimized. We checked the ability of one method for the analysis of a fixed‐dose combination composed by emtricitabine/tenofovir/efavirenz in tablet formulations. Satisfying validation results were obtained by applying the total error approach taking into account the accuracy profile as decision tool. Then, the validated method was applied to test two samples coded A and B, and claimed to contain the tested ARV. Assay results were satisfying only for sample B.
American Journal of Tropical Medicine and Hygiene | 2018
Benedetta Schiavetti; Evelien Wynendaele; Jérémie Mbinze Kindenge; Nicodème Kalenda Tshilombo; Roland Marini Djang'Eing'A; Vera Melotte; Epco Hasker; Bruno Meessen; Raffaella Ravinetto; Bart De Spiegeler; Josiane Van der Elst; Daniel Ngeleka Mutolo
Abstract. Poor-quality medicines are a threat to public health in many low- and middle-income countries, and prospective surveys are needed to inform corrective actions. Therefore, we conducted a cross-sectional survey on a sample of products used for children and available in the private market in Kinshasa, Democratic Republic Congo: amoxicillin (AX) and artemether/lumefantrine (AL), powders for suspension, and paracetamol (PC) tablets 500 mg. Overall, 417 products were covertly purchased from 61 wholesalers. To obtain a representative sample, the products were weighted on their market shares and a subset of 239 samples was randomly extracted to undergo in-depth visual inspection locally, and they were chemically assessed at two accredited laboratories in Belgium. Samples were defined of “poor-quality” if they failed to comply with at least one specification of the International Pharmacopoeia (for AL) or United States Pharmacopoeia 37 (for AX and PC). Results are reported according to the Medicine Quality Assessment Reporting Guideline. The visual inspection detected nonconformities in the aspects of antimalarial powders for suspension, and poor-quality labels across all medicine types. According to chemical analysis, 27.2% samples were of poor quality and 59.5% of AL samples were underdosed in artemether. Poor quality was more frequent for locally manufactured antimalarials (83.3%, P = 0.021; 86.4%, P = 0.022) and PC (4.8%, P = 0.000). The poor quality of the surveyed products may decrease the treatment’s efficacy and favor the development of resistances to antimalarials. It is hoped that these findings may guide the corrective actions of the Democratic Republic of Congo Regulatory Authority, which was the main partner in the research.
American Journal of Analytical Chemistry | 2015
Védaste Habyalimana; Jérémie Mbinze Kindenge; Nicodème Kalenda Tshilombo; Amandine Dispas; Achille Yemoa Loconon; Pierre-Yves Sacre; Joëlle Widart; Pascal De Tullio; Stéphane Counerotte; Justin-Léonard Kadima Ntokamunda; Eric Ziemons; Philippe Hubert; Roland Marini Djang'Eing'A
Archive | 2018
Roland Marini Djang'Eing'A; Don Jethro Mavungu Landu; Abdoul Karim Sakira; Pierre-Yves Sacre; Nicodème Kalenda Tshilombo; Philippe Hubert
American Journal of Analytical Chemistry | 2018
Nicodème Kalenda Tshilombo; Patient Ciza Hamuli; Jérémie Kindenge Mbinze; Védaste Habyalimana; Dibungi T. Kalenda; Don Jethro Mavungu; Pierrot Mwamba; Philippe Hubert; R.D. Marini
Archive | 2017
Roland Marini Djang'Eing'A; Nicodème Kalenda Tshilombo; Patient Ciza Hamuli; Don Jethro Mavungu Landu; Pierre-Yves Sacré; Philippe Hubert
Archive | 2017
Nicodème Kalenda Tshilombo; Patient Ciza Hamuli; Don Jethro Mavungu Landu; Pierrot Mwamba; Christelle Waffo; Diallo Tidiane; Jérémie Kindenge Mbinze; Philippe Hubert; Roland Marini Djang'Eing'A
Archive | 2017
Roland Marini Djang'Eing'A; Nicodème Kalenda Tshilombo; Patient Ciza Hamuli; Don Jethro Mavungu Landu; Pierre-Yves Sacre; Philippe Hubert
Archive | 2016
Nicodème Kalenda Tshilombo; Christelle Waffo Tchounga; Tidiane Diallo; Jérémie Mbinze Kindenge; Pascal Dibungi T. Kalenda; Philippe Hubert; Roland Marini Djang'Eing'A
Archive | 2015
Nicodème Kalenda Tshilombo; Jérémie Mbinze Kindenge; T.D. Kalenda; Tayey Mbay Jean Mavar; Philippe Hubert; Roland Marini Djang'Eing'A